2.1
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older'.
2 Information about fenfluramine
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for fenfluramine.
Price
2.3
The list price for fenfluramine is £1,802.88 for the 120‑ml (2.2 mg/ml) bottle and £5,408.65 for the 360‑ml bottle (excluding VAT; BNF online accessed January 2025).
2.4
The company has a commercial arrangement. This makes fenfluramine available to the NHS with a discount. The size of the discount is commercial in confidence.